This report looks at state and federal laws and policies that encourage braided funding to provide substance use disorder services, best practices for braiding funds, and pathways to sustainability for substance use disorder programs.

This report provides an update on the present state of coverage, availability of, and access to, medications for treating ongoing alcohol use disorder (AUD) and opioid use disorder (OUD) and reversing an opioid overdose within state Medicaid plans. It also includes examples of innovative efforts to increase access to medications for the treatment of SUDs.

This report explores the use of Value-Based Payment (VBP) model and the potential to improve delivery of integrated and coordinated substance use disorder (SUD) treatment services.

An analysis of the 2022 DAWN data presents nationally representative weighted estimates of all drug-related emergency department (ED) visits, nationally representative weighted estimates of the top substances involved in drug-related ED visits, including rates by race and ethnicity; nationally representative weighted estimates of opioid- related ED visits by type of opioid, drugs involved in polysubstance ED visits, and the identification of newly mentioned drugs in 2022.

An analysis of final 2021 DAWN data presents: (1) nationally representative weighted estimates, including percent and unadjusted rates per 100,000, for all drug-related emergency department (ED) visits, (2) nationally representative weighted estimates for the top five drugs in drug-related ED visits, (3) the assessment of monthly trends and drugs involved in polysubstance ED visits in a subset of sentinel hospitals, and (4) the identification of drugs new to DAWN’s Drug Reference Vocabulary.

An analysis of 2021 preliminary data presents (1) nationally representative weighted estimates for the top five drugs in drug-related ED visits, (2) the assessment of monthly trends and drugs involved in polysubstance ED visits in a subset of sentinel hospitals, and (3) the identification of drugs new to DAWN’s Drug Reference Vocabulary.

The report discusses Medicaid coverage of FDA-approved medications for treatment of alcohol and opioid use disorders, limitations on coverage (such as prior authorization requirements), background on federal laws and policies and innovative practices and policies at the state level.

The report highlights the need for HIV treatment providers to address behavioral health concerns with HIV. The report urges providers to start with screening for mental health and substance use disorders, and offers strategies for providers to implement screening practices.

This executive summary of the Surgeon General's Report on Alcohol, Drugs, and Health addresses alcohol, illicit drugs, and prescription drug misuse in the United States. Chapters of the report cover neurobiology, prevention, treatment, recovery, health systems integration, and recommendations for the future.

This Surgeon General's Report on Alcohol, Drugs, and Health addresses the prevalence of alcohol, illicit drugs, and prescription drug misuse in the United States. Chapters of the report cover neurobiology, prevention, treatment, recovery, health systems integration, and recommendations for the future.